Antitumor activity of Enzastaurin (LY317615) in human tumor xenografts in vitro

被引：1
|
作者：
Maier, A.
Fiebig, H. H.
Thornton, D.
Lahn, M.
机构：
[1] Oncotest GmbH, Inst Expt Oncol, Freiburg, Germany
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
EJC SUPPLEMENTS | 2006年 / 4卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(06)70621-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
616
引用
收藏
页码：186 / 186
页数：1
相关论文
共 50 条
  • [1] A PHASE I TRIAL OF ENZASTAURIN (LY317615) IN PATIENTS WITH RECURRENT GLIOMAS
    Kreisl, Teri
    Kim, Lyndon
    Heinrich, Elinzano
    Royce, Cheryl
    Stroud, Irene
    Nancy, Garren
    Albert, Paul
    Musily, Luna
    Thornton, Donald E.
    Fine, Howard
    NEURO-ONCOLOGY, 2008, 10 (05) : 786 - 786
  • [2] The PKCβ selective inhibitor, enzastaurin (LY317615), inhibits growth of human lymphoma cells.
    Rossi, RM
    Henn, AD
    Conkling, R
    Guzman, ML
    Bushnell, T
    Harvey, J
    Fisher, RI
    Jordan, CT
    BLOOD, 2005, 106 (11) : 427A - 427A
  • [3] Molecular targeting of the PKC-β inhibitor enzastaurin (LY317615) in multiple myeloma
    Verdelli, D.
    Nobili, R. L.
    Civallero, M.
    Cosenza, M.
    Todoerti, K.
    Bertacchini, J.
    Lombardi, L.
    Marmiroli, S.
    Federico, M.
    De Pol, A.
    Lambertenghi-Deliliers, G.
    Tassone, P.
    Neri, A.
    Sacchi, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 258 - 258
  • [4] A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas
    Odia, Yazmin
    Iwamoto, Fabio M.
    Moustakas, Argirios
    Fraum, Tyler J.
    Salgado, Carlos A.
    Li, Aiguo
    Kreisl, Teri N.
    Sul, Joohee
    Butman, John A.
    Fine, Howard A.
    JOURNAL OF NEURO-ONCOLOGY, 2016, 127 (01) : 127 - 135
  • [5] A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas
    Yazmin Odia
    Fabio M. Iwamoto
    Argirios Moustakas
    Tyler J. Fraum
    Carlos A. Salgado
    Aiguo Li
    Teri N. Kreisl
    Joohee Sul
    John A. Butman
    Howard A. Fine
    Journal of Neuro-Oncology, 2016, 127 : 127 - 135
  • [6] A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054)
    Rampling, Roy
    Sanson, Marc
    Gorlia, Thiery
    Lacombe, Denis
    Lai, Christina
    Gharib, Myriam
    Taal, Walter
    Stoffregen, Clemens
    Decker, Rodney
    van den Bent, Martin J.
    NEURO-ONCOLOGY, 2012, 14 (03) : 344 - 350
  • [7] Phase I dose escalation and pharmacokinetic study of oral enzastaurin (LY317615) in advanced solid tumors
    Mukohara, Toru
    Nagai, Shunji
    Koshiji, Minori
    Yoshizawa, Kenichi
    Minami, Hironobu
    CANCER SCIENCE, 2010, 101 (10) : 2193 - 2199
  • [8] Phase 1 study of LY317615 (enzastaurin) and temozolomide in patients with gliomas - EORTC trial 26054
    Rampling, R.
    Sanson, M.
    Taal, W.
    Lai, C.
    Stoffregen, C.
    Munoz, M.
    Gorlia, T.
    Govaerts, A.
    Lacombe, D.
    Van den Bent, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers
    Gray, Jhanelle E.
    Altiok, Soner
    Alexandrow, Mark G.
    Walsh, Frank W.
    Chen, Jian
    Schell, Michael J.
    Tai, Datchen Fritz
    Bepler, Gerold
    CANCER, 2013, 119 (05) : 1023 - 1032
  • [10] ENZASTAURIN (LY317615), A PROTEIN KINASE C BETA SELECTIVE INHIBITOR, ENHANCES ANTIANGIOGENIC EFFECT OF RADIATION
    Willey, Christopher D.
    Xiao, Dakai
    Tu, Tianxiang
    Kim, Kwang Woon
    Moretti, Luigi
    Niermann, Kenneth J.
    Tawtawy, Mohammed N.
    Quarles, Chad C.
    Lu, Bo
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 77 (05): : 1518 - 1526
12345